



# aTyr Pharma

## **aTyr Pharma to Present at Two Upcoming Investor Conferences in September**

September 6, 2017

SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new pathway insights from human Physiocrine proteins, to treat patients suffering from severe, rare immune-mediated diseases, as well as various cancers, today announced its participation at two investor conferences in September:

- A fireside chat at the 2017 Wells Fargo Healthcare Conference in Boston on Wednesday, September 6, at 8:30 a.m. Eastern Time.
- A presentation at Ladenburg Thalmann's 2017 Healthcare Conference in New York City on Tuesday, September 26 at 11:30 a.m. Eastern Time. This presentation will be webcast live through the "Investors" section of the aTyr Pharma website at [www.atyrpharma.com](http://www.atyrpharma.com). An audio replay will be available for at least 30 days following the initial presentation webcast.

### **About aTyr Pharma**

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients using its knowledge of Physiocrine biology, a newly discovered set of immunological and physiological pathways. To date, aTyr has generated three innovative therapeutic programs with three different biologic modalities based on its knowledge of the Resokine pathway to treat patients suffering from severe, rare immune-mediated diseases, as well as various cancers. The Resolaris and iMod.Fc programs are agonists of the Resokine pathway designed to temper immune system engagement in diseases characterized by excessive immune cell involvement. aTyr's third program, ORCA, represents a novel, proprietary pathway in immuno-oncology that utilizes antibody approaches to block the Resokine pathway and 'release multiple brakes' on the immune system in the tumor cell environment. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 220 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential Physiocrine-based protein compositions. For more information, please visit <http://www.atyrpharma.com>.

Contact:

Mark Johnson  
Sr. Director, Investor Relations  
[mjohnson@atyrpharma.com](mailto:mjohnson@atyrpharma.com)  
858-223-1163

 [Primary Logo](#)

aTyr Pharma Inc.